Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-539313 in Moderate to Severe Binge Eating Disorder
NCT04753164Phase 2Completed
- Sponsor
- Idorsia
- Start
- Feb 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in binge eating disorder (BED) comparing ACT-539313 with Placebo (2 arms). Primary endpoint: Change From Baseline to Week 12 in the Number of Binge Eating (BE) Days Per Week. Started Feb 2021; status: completed.
02
Drugs
nivasorexant
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT04753164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04753164.